Diagnostic performance of guaiac-based fecal occult blood test in routine screening: State-wide analysis from bavaria, Germany

American Journal of Gastroenterology

Volumn 109, Issue 3, 2014, Pages 427-435

  Brenner, Hermann ^a   Hoffmeister, Michael ^a   Birkner, Berndt ^b,c   Stock, Christian ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Gastroenterological Practice   (Germany)

^c Association of Statutory Health Insurance Physicians Bavaria   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; FEMALE; GERMANY; GROUPS BY AGE; GUAIAC-BASED FECAL OCCULT BLOOD TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OCCULT BLOOD TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GERMANY; GUAIAC; HUMANS; INDICATORS AND REAGENTS; MALE; MIDDLE AGED; OCCULT BLOOD; SENSITIVITY AND SPECIFICITY;

EID: 84895833455     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.424     Document Type: Article

References (38)

1. Hewitson P, Glasziou P, Watson E et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103: 1541-9.
2. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-14.
3. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-9.
4. Park DI, Ryu S, Kim YH et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017-25.
5. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press: Oxford New York, 2003.
6. Brenner H, Tao S. Superior diagnostic performance of fecal immunochemical tests for hemoglobin in a head-to-head comparison with guaiac based fecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013; 49: 3049-54.
7. Mansmann U, Crispin A, Henschel V et al. Epidemiology and quality control of 245000 outpatient colonoscopies. Dtsch Arztebl Int 2008; 105: 434-40.
8. Crispin A, Birkner B, Munte A et al. Process quality and incidence of acute complications in a series of more than 230, 000 outpatient colonoscopies. Endoscopy 2009; 41: 1018-25.
9. Kolligs FT, Crispin A, Munte e A et al. Risk of advanced colorectal neoplasia according to age and gender. PLoS ONE 2011; 6: e20076.
10. Stock C, Hoff meister M, Birkner B et al. Utilization and yield of neoplasms in colonoscopies performed within 3 years after screening colonoscopy: a historical cohort study. Endoscopy 2013; 45: 537-46.
11. Pox CP, Altenhofen L, Brenner H et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012; 142: 1460-7.
12. Qaseem A, Denberg TD, Hopkins RH Jr et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012; 156: 378-86.
13. Rabeneck L, Rumble RB, Th ompson F et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012; 26: 131-47.
14. Van Rijn JC, Reitsma JB, Stoker J et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101: 343-50.
15. Pickhardt PJ, Hassan C, Halligan S et al. Colorectal cancer: CT colonography and colonoscopy for detection-systematic review and meta-analysis. Radiology 2011; 259: 393-405.
16. Rosman AS, Korsten MA. Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis. J Gen Intern Med 2010; 25: 1211-21.
17. Stock C, Ihle P, Schubert I et al. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort. Endoscopy 2011; 43: 771-9.
18. Zavoral M, Suchanek S, Zavada F et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009; 15: 5907-15.
19. Steele RJ, McClemments PL, Libby G et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009; 58: 530-5.
20. Wong CK, Fedorak RN, Prosser CI et al. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis 2012; 27: 1657-64.
21. Garborg K, Holme Ø., Løberg M et al. Current status of screening for colorectal cancer. Ann Oncol 2013; 24: 1963-72.
22. van Dam L, Kuipers EJ, van Leerdam ME. Performance characteristics of stool-based screening tests. Best Pract Res Clin Gastroenterol 2010; 24: 479-92.
23. Pox C. Colon cancer screening: which non-invasive filter tests? Dig Dis 2011; 29 (Suppl 1): 56-9.
24. Duffy MJ, van Rossum LGM, van Turenhout ST et al. Use of fecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Int J Cancer 2011; 128: 3-11.
25. Imperiale TF. Noninvasive screening tests for colorectal cancer. Dig Dis 2012; 30 (Suppl 2): 16-26.
26. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
27. Levi Z, Birkenfeld S, Vilkin A et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. Int J Cancer 2011; 128: 2415-24.
28. Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-8.
29. Vart G, Banzi R, Minozzi S. Comparing participation rates between immunochemical and guaiac faecal occult blood tests: a systematic review and meta-analysis. Prev Med 2012; 55: 87-92.
30. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
31. Segnan N, Armaroli P, Bonelli L et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst 2011; 103: 1310-22.
32. Schoen RE, Pinsky PF, Weissfeld JL et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-57.
33. Brenner H, Chang-Claude J, Seiler CM et al. Protection from colorectal cancer after colonoscopy: population-based case-control study. Ann Intern Med 2011; 154: 22-30.
34. Zauber AG, Winawer SJ, O ' Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687-96.
35. Allison JE, Fraser CG, Halloran SP et al. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012; 143: 422-4.
36. Stock C, Brenner H. Utilization of lower gastrointestinal endoscopy and fecal occult blood test in 11 European countries. Endoscopy 2010; 42: 546-56.
37. Rao SK, Schilling TF, Sequist TD. Challenges in the management of positive fecal occult blood tests. J Gen Intern Med 2009; 24: 356-60.
38. Choi KS, Lee HY, Jun JK et al. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008. J Gastroenterol Hepatol 2012; 27: 1070-7.